Результаты поиска

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.

BACKGROUND: Standard therapy for human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC) is lacking. The clinical benefits with pan-HER inhibitors (afatinib, neratinib, and dacomitinib), anti-HER2 antibody drug conjugate (ADC) trastuzumab emtansine, and an emerging irreversible tyrosine kinase inhibitor (TKI) poziotinib were modest. Another new ADC trastuzumab deruxtecan showed encouraging outcomes, but only phase I study was completed. Pyrotinib, another emerging irreversible epidermal growth factor receptor (EGFR)/HER2 dual TKI, has been approved in HER2-pos

Совпадение в полном тексте источника
… Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC. Eur J Pharmacol. 2019;856:172409. doi: 10.1016/j.ejphar.2019.172409. 24. Wang G-H, Wu P-F, Zhang L-H, Fang P, Chen Y, Zuo G, Wu Y-Q, Wang S-H, Sun G-P. …

Parasites revive hope for cancer therapy.

Parasites have attained a life-long stigma of being detrimental organisms with deleterious outcomes. Yet, recently, a creditable twist was verified that can dramatically change our perception of those parasites from being a source of misery to millions of people to a useful anti-cancerous tool. Various parasites have shown promise to combat cancer in different experimental models, including colorectal, lung, and breast cancers, among others. Helminths and protozoan parasites, as well as their derivatives such as Echinococcus granulosus protein KI-1, Toxoplasma gondii GRA15II, and Trypanosoma c

Совпадение в полном тексте источника
… as demonstrated by significant apoptosis and decreased viability of cells and significant inhibition of autophagy [ 168 ] Plasmodium circumsporozoite protein overexpression In vivo Synergistically inhibited cancer growth by enhancing the chemotherapeutic effect of gefitinib by inhibition of autophagy … as demonstrated by significant apoptosis and decreased viability of cells and significant inhibition of autophagy | [ 168 ] Plasmodium circumsporozoite protein overexpression | In vivo | Synergistically inhibited cancer growth by enhancing the chemotherapeutic effect of gefitinib by inhibition of autophagy …

Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer.

Epigenetics shapes all aspects of cancer occurrence and progression. Among them, chromatin methylation is a particularly important regulator of oncogenic processes. The dynamic shifts in methylation can influence the development or death of tumor cells. In the therapeutic context, effectively targeting and modulating DNA, RNA, and histone methylation brings promise for the early detection, prognostic assessment, and treatment of cancer. In particular, novel methylation inhibitors or modulators powerfully kill tumor cells or improve existing therapeutic strategies through different signaling pa

Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma.

We would like to highlight the application of natural products to hepatocellular carcinoma (HCC). We will focus on the natural products known as flavonoids, which target this disease at different stages of hepatocarcinogenesis. In spite of the use of chemotherapy and radiotherapy in treating HCC, patients with HCC still face poor prognosis because of the nature of multidrug resistance and toxicity derived from chemotherapy and radiotherapy. Flavonoids can be found in many vegetables, fruits, and herbal medicines that exert their different anticancer effects via different intracellular signalin

Совпадение в полном тексте источника
… In contrast, Gu et al. have demonstrated that combination treatments with silibinin enhance the growth-inhibitory effects of both gefitinib and sorafenib, which may be attributable to the inhibition of EGFR-dependent Akt signaling [ 30 ]. … Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells Clinical and Molecular Hepatology 2015 21 1 49 59 10.3350/cmh.2015.21.1.49 25834802 PMC4379197 31 Rigalli J. P. Ciriaci N. Arias A. …

Renal Involvement in Cancer Patients Undergoing Oncology Therapies: Implications for Personalized Treatment Strategies.

Introduction: Oncological therapies have significantly improved patient outcomes but are increasingly associated with renal toxicity, which can markedly influence therapeutic decisions. Integrating early identification of kidney injury into clinical workflows is essential for personalized medicine, allowing treatment tailoring based on individual risk profiles. Aim: To evaluate the incidence of acute kidney injury (AKI) and chronic kidney Disease (CKD); assess indices of renal function recovery in patients who developed AKI; and investigate the incidence of renal immune-related adverse events

Совпадение в полном тексте источника
… Modern oncological treatment includes a broad range of therapeutic strategies such as conventional chemotherapy (e.g., irinotecan, capecitabine, oxaliplatin, gefitinib, erlotinib, gemcitabine, cisplatin, paclitaxel, carboplatin, docetaxel, vinorelbine, topotecan, etoposide); targeted therapies aimed …

The relationship between Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 12 (SNHG12) expression in solid malignant tumors and prognosis of tumor patients: A systematic review and meta-analysis.

BackgroundSmall nucleolar RNA host gene 12 (SNHG12) has been demonstrated to be a long noncoding RNA (lncRNA) that facilitates the progression of several solid malignant tumors. However, whether the expression level of SNHG12 in solid malignant tumors is associated with patients prognosis have not been investigated.MethodsWe systematically searched PubMed, EMBASE and Cochrane Library from Jan 1, 1950 to Mar 24, 2020 for randomized controlled trials published in English on SNHG12 expression in solid malignant tumors. We used the Newcastle-Ottawa Scale to assess the quality of articles. The HRs

Совпадение в полном тексте источника
… Many targeted drugs aimed at specific targets have been brought out, such as Gefitinib, which targets the epidermal growth factor receptor tyrosine kinase, and Imatinib, a BCR-ABL tyrosine kinase inhibitor. …

Female sex is associated with a lower risk of bone metastases and favourable prognosis in non-sex-specific cancers.

BackgroundThe objectives were to investigate the disparity in the prevalence of bone metastases (BM) between the sexes and to assess the effect of female sex on the development and prognosis of BM.MethodsCases of invasive non-sex-specific cancers diagnosed between 2010 and 2015 in the Surveillance, Epidemiology, and End Results (SEER) program were used. The prevalence of BM was calculated by combining the prevalence of BM among different cancers. Multivariable logistic regression and proportion hazard regression were conducted to investigate the effect of female sex, and the results were poole

Совпадение в полном тексте источника
… Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23(11):2513–2520. doi: 10.1200/JCO.2005.00.992. 36. …

Analysis of 2023 World Health Organization cancer Essential Medicines List and concordance with resource-stratified guidelines.

BackgroundThe World Health Organization (WHO) Essential Medicines List (EML) and resource-stratified guidelines both prioritize high-value medicines. We compared the 2023 EML cancer medicines list with global cancer statistics, examined the proportion of EML therapies recommended by resource-stratified guidelines, and identified gaps that merit evaluation by the WHO EML Committee.MethodsWe compared the 2023 EML medicines for adult cancers with cancer incidence and mortality data from GLOBOCAN 2022. We cross-referenced the EML with 2 resource-stratified guidelines (National Comprehensive Cancer

Совпадение в полном тексте источника
… Oxaliplatin | | | | Irinotecan | | | | Calcium folinate | | | | Capecitabine | | | | Non–small cell lung cancer ( n = 7) | Cisplatin | | | | Carboplatin | | | | Etoposide | | | | Gemcitabine | | | | Paclitaxel | | | | Vinorelbine | | | | Erlotinib (alternatives: gefitinib …

When Should Spinal Surgery Be Considered for Spinal Metastasis from Non-Small Cell Lung Cancer?-Propensity Score Matched Study between Surgery with Radiotherapy and Radiotherapy Alone.

(1) Background: Although metastatic spine disease is increasing, the debate on therapeutic modality remains due to the heterogeneity of tumors and patients. This study aims to evaluate the efficacies of surgery and risk factors for patients' survival from potentially unstable spinal metastasis of non-small cell lung cancer; (2) Methods: Twenty-two patients undergoing surgery and radiotherapy (group I) were compared with 22 patients undergoing radiotherapy alone (group II) using propensity score matching in a 1-to-1 format. Clinical outcomes included the performance status and ambulatory status

Совпадение в полном тексте источника
… EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500. doi: 10.1126/science.1099314. 23. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., et al. …

A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.

Multiple myeloma (MM), the second most common haematological malignancy, is currently incurable because patients often develop multiple drug resistance and experience subsequent relapse of the disease. This study aims to identify a potential therapeutic agent that can counter bortezomib (BTZ) resistance in MM. DCZ0358, a novel alkaloid compound, is found to exert potent cytotoxic effects against BTZ-resistant MM cells in vivo and in vitro. The anti-myeloma activity of DCZ0358 is associated with inhibition of cell proliferation, promotion of cell apoptosis via caspase-mediated apoptotic pathway

Совпадение в полном тексте источника
… Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3. Cancer Lett . . 2016;379:124–133. doi: 10.1016/j.canlet.2016.06.002. 29. Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, et al. …

Surgical treatment in malignant pleural effusion.

Malignant pleural effusion can be described as the presence of exudate in the pleural space, accompanied by the detection of cancer cells in pleural fluid or tissue, which is the indicator of the disease in its advance stages, and survival time of these patients ranges between 3 and 12 months. Treatment options for malignant pleural effusion vary from observation in asymptomatic patients to pleurectomies or even extrapleural pneumonectomies in severe cases.

Совпадение в полном тексте источника
… gives rise to an inflammatory response, thereby, leading to the increased microvascular permeability.[ 2 ] In general, MPE is common in patients with EGFR mutations and anaplastic lymphoma kinase (ALK) fusion.[ 23 , 24 ] EGFR or ALK mutations patients respond better to tyrosine kinase inhibitors (TKIs; gefitinib …

The emergence of new prognostic scores in lung cancer patients with spinal metastasis: A 12-year single-center retrospective study.

Objective: Lung cancer patients exhibit spinal metastases from a specific population, and with this study, we aimed to develop a model that can predict this particular group's survival. Methods: Data were retrospectively collected from 83 lung cancer patients who underwent spinal metastasis surgery at our center from 2009 to 2021. After the initial assessment of treatment and scoring effects, a nomogram for survival prediction was created by identifying and integrating critical prognostic factors, followed by a consistency index (C-index) to measure consistency, and finally, a subject working

Совпадение в полном тексте источника
… Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8. doi: 10.1016/S1470-2045(09)70364-X. 33. …

Effect of a Mobile App for the Pharmacotherapeutic Follow-Up of Patients With Cancer on Their Health Outcomes: Quasi-Experimental Study.

BackgroundOral antineoplastic agents (OAAs) have revolutionized cancer management. However, they have been reported with adverse side effects and drug-drug interactions. Moreover, patient adherence to OAA treatment is critical. Mobile apps can enable remote and real-time pharmacotherapeutic monitoring of patients, while also promoting patient autonomy in their health care.ObjectiveThe primary objective was to analyze the effect of using a mobile app for the follow-up of patients with oncohematological malignancies undergoing treatment with OAAs on their health outcomes. The secondary objective

Совпадение в полном тексте источника
… .15 | No | 51 (100) | 48 (96) | 99 (98.0) | | Yes | 0 (0) | 2 (4) | 2 (2.0) | Living alone | .13 | No | 39 (77) | 44 (88) | 83 (82.2) | | Yes | 12 (24) | 6 (12) | 18 (17.8) | Treatment | .001 a | Lenalidomide | 15 (29) | 4 (8) a | 19 (18.8) | | Pazopanib | 8 (16) | 3 (6) | 11 (10.9) | | Gefitinib …

Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.

BackgroundOne of the functions of the reformed Cancer Drugs Fund in England is as a managed access fund, providing conditional funding for cancer drugs where there is uncertainty in the economic case, and where that uncertainty can be addressed by data collection during two years' use in the NHS. Our study characterises likely sources of such uncertainty, through a review of recent NICE Technology Appraisals.MethodsDiscussions of uncertainty in NICE Appraisal Committees were extracted from published Single Technology Appraisals of cancer drugs, 2014-2016, and categorised inductively. The locat

Совпадение в полном тексте источника
… NICE Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374) 2015 10.3310/hta19470 PMC4781386 26134145 33. …

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.

The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with myelodysplastic syndromes (MDS) associated with deletion 5q cytogenetic abnormality, as part of the Institute's single technology appraisal (STA) process. Kleijnen Systematic Reviews Ltd (KSR), in collaboration with Erasmus University Rotterdam, was commissioned to act as the Evidence Review Group (ERG). This paper describes the company's submission, the ERG review, and the NICE's subsequen

Совпадение в полном тексте источника
… Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Health Technol Assess. 2015;19(47):1–134. doi: 10.3310/hta19470. 7. …

High Risk-Human Papillomavirus in HNSCC: Present and Future Challenges for Epigenetic Therapies.

Head and Neck Squamous Cell Carcinoma (HNSCC) is a highly heterogeneous group of tumors characterized by an incidence of 650,000 new cases and 350,000 deaths per year worldwide and a male to female ratio of 3:1. The main risk factors are alcohol and tobacco consumption and Human Papillomavirus (HPV) infections. HNSCC cases are divided into two subgroups, the HPV-negative (HPV-) and the HPV-positive (HPV+) which have different clinicopathological and molecular profiles. However, patients are still treated with the same therapeutic regimens. It is thus of utmost importance to characterize the mo

Совпадение в полном тексте источника
… pre-clinical data are indicating several other epigenetic enzymes as potential novel targets for HNSCC such as LSD1, BRD4, KDM6A, the NSD family members, alone or in combination with other approved epigenetic inhibitors, immunotherapies, chemo- or radiotherapies or targeted therapies, such as cetuximab or gefitinib … Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: A key role for DeltaNp63alpha Br. J. Cancer 2019 120 658 667 10.1038/s41416-019-0394-9 30765872 PMC6461861 123. AlSaqer S.F. Tashkandi M.M. Kartha V. Yang Y.-T. Alkheriji Y. Salama A. …

Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions.

The tumor microenvironment (TME) is a complex system composed of multiple cells, such as non-cancerous fibroblasts, adipocytes, immune and vascular cells, as well as signal molecules and mediators. Tumor cells recruit and reprogram other cells to produce factors that maintain tumor growth. Communication between cancerous and surrounding cells is a two-way process and engages a diverse range of mechanisms that, in consequence, can lead to rapid proliferation, metastasis, and drug resistance, or can serve as a tumors-suppressor, e.g., through tumor-immune cell interaction. Cross-talk within the

Совпадение в полном тексте источника
… However, vorinostat, in combination with gefitinib, showed synergistic cytotoxicity in lung adenocarcinoma and hepatocarcinoma with mutant KRAS [ 174 ]. Similarly, anakinra, an IL-1 blocker, is applied as a treatment in many diseases such as rheumatoid arthritis, infections, and type 2 diabetes. … Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. Onco Targets Ther. 2016;9:6843–6855. doi: 10.2147/OTT.S117743. 175. …

Novel immunotherapeutic strategies of gastric cancer treatment.

Gastric cancer (GC) is the fourth most common cancer and the second most frequent cause of cancer-related deaths, accounting for 10.4% of cancer deaths worldwide. Despite the improvements, estimated cure rates for patients with advanced stages remain poor, and in the metastatic setting, chemotherapy is the mainstay of palliative therapy and results in objective response rates (ORRs) of only 20-40% and median overall survivals (OS) of 8-10 months. Therefore, many investigators believe that the potential for making significant progress lies in understanding and exploiting the molecular biology o

Совпадение в полном тексте источника
… Current anti-EGFR therapies that have been evaluated in EGCs include oral TK inhibitors (TKIs: erlotinib, gefitinib) and monoclonal antibodies (moAbs: cetuximab, panitumumab, and matuzumab). … Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. Journal of Clinical Oncology. 2006;24(10):1612–1619. doi: 10.1200/JCO.2005.03.4900. 119. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. …

Targeting Autophagy Using Long Non-Coding RNAs (LncRNAs): New Landscapes in the Arena of Cancer Therapeutics.

Cancer has become a global health hazard accounting for 10 million deaths in the year 2020. Although different treatment approaches have increased patient overall survival, treatment for advanced stages still suffers from poor clinical outcomes. The ever-increasing prevalence of cancer has led to a reanalysis of cellular and molecular events in the hope to identify and develop a cure for this multigenic disease. Autophagy, an evolutionary conserved catabolic process, eliminates protein aggregates and damaged organelles to maintain cellular homeostasis. Accumulating evidence has implicated the

Совпадение в полном тексте источника
… Cancer | MSTO2P | Clinical | Lung cancer tissues | Up | [ 180 ] In vitro | H1299, H23, and A549 | Up LCPAT1 | In vitro | CSE- or PM2.5-induced H1299 and H520 | Up | [ 181 ] PANDAR | Clinical | Lung cancer tissues | Down | [ 182 ] In vitro | L78, PC9, 95D, NCI-H460, and A549 | Down MITA1 | In vitro | Gefitinib-resistant … Migration, ↓Invasion, Autophagy halted after CSE/ PM2.5 exposure | [ 181 ] | LINC00857 b | YBX1 | ↓Proliferation, ↑LC3 II/I ratio, ↑cle-PARP, ↓YBX1, ↓p-MET, ↑p-AMPKa | [ 218 ] | PANDAR a | - | ↓Proliferation, ↑Autophagy, ↑Beclin-1 | [ 182 ] | MITA1 a | - | ↓Apoptosis, ↑LC3 II/I ratio, ↑Beclin-1, ↓p62, ↑Gefitinib …

Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer.

One of the primary diseases that cause death worldwide is cancer. Cancer cells can be intrinsically resistant or acquire resistance to therapies and drugs used for cancer treatment through multiple mechanisms of action that favor cell survival and proliferation, becoming one of the leading causes of treatment failure against cancer. A promising strategy to overcome chemoresistance and radioresistance is the co-administration of anticancer agents and natural compounds with anticancer properties, such as the polyphenolic compound resveratrol (RSV). RSV has been reported to be able to sensitize c

Совпадение в полном тексте источника
… Another interesting study is that of Weiguo ( Zhao et al., 2010 ), who analyzed the efficacy of RSV with non-small cell lung cancer cells or NSCLC (SPC-A-1/CDDP) resistant to multiple drugs (Paclitaxel, taxol, gefitinib, cisplatin, etc.). … RSV significantly inhibited the proliferation of NSCLC cells, induced apoptosis, arrested the cell cycle between G0-G1 and S phases or in the G2/M phase, and decreased IC50 values of chemotherapeutic drugs (cisplatin, gefitinib, and paclitaxel) ( Gupta et al., 2011 ). …